Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $77.00 target price on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 301.46% from the […]

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at […]

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 12.36% from the stock’s current price. Several other research […]

HC Wainwright reiterated their neutral rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a research note published on Wednesday morning,Benzinga reports. They currently have a $1.00 target price on the stock, down from their prior target price of $6.00. Several other equities analysts also recently commented on SYRS. TD Cowen restated a […]